Related Experiment Video

Updated: Nov 2, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.1K

Correction to: Genetic updates on paroxysmal dyskinesias

James Y Liao1, Philippe A Salles1,2, Umar A Shuaib1

  • 1Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.

Journal of Neural Transmission (Vienna, Austria : 1996)
|June 12, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.6K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K

Related Experiment Videos

Last Updated: Nov 2, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.1K
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.6K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.0K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

606
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
606

Articles linked to this work by shared authors, journal, and citation graph.

Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.

The Lancet. Neurology·2026

Integrating Eye Tracking and Inertial Sensing for Enhanced Freezing of Gait Detection in Parkinson's Disease.

The European journal of neuroscience·2026

Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.

JAMA neurology·2026

Closing the Gate Before the Horse is out of the Barn: A Model to Effectively Predict the First Fall in Patients with Parkinson's Disease.

Movement disorders clinical practice·2026

Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center.

Parkinsonism & related disorders·2026

A novel methodological approach to understanding the cortical and subcortical effects of aerobic exercise in Parkinson's disease.

Frontiers in human neuroscience·2025

Cerebellar ataxia in the Philippines: a scoping review of reported cases and practical approach.

Journal of neural transmission (Vienna, Austria : 1996)·2026

Real-world gait changes preceding Parkinson's disease diagnosis in a population-scale UK biobank cohort.

Journal of neural transmission (Vienna, Austria : 1996)·2026

Age-, sex-, and stroke type-specific associations of lifestyle factors with 30-day poststroke case-fatality: a nationwide cohort study.

Journal of neural transmission (Vienna, Austria : 1996)·2026

Quality management and specifications of multidisciplinary Parkinson's disease management: an expert opinion.

Journal of neural transmission (Vienna, Austria : 1996)·2026

Reduced glymphatic function in autism revealed by the diffusion tensor analysis along the perivascular space index.

Journal of neural transmission (Vienna, Austria : 1996)·2026

Multimodal assessment of clinical and neural changes following multidisciplinary management in functional motor disorders.

Journal of neural transmission (Vienna, Austria : 1996)·2026

Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.

Molecular therapy. Oncology·2026

In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing.

Molecular therapy. Advances·2026

m6A-dependent regulation of DGUOK-AS1 by RBM15 and HNRNPH1 in lung adenocarcinoma.

iScience·2026

Metabolic reprogramming in pancreatic cancer: interplay of glucose, lipid, and amino acid metabolism in tumor progression.

Cytotechnology·2026

Baicalein targets the Nrf2/Keap1 interaction and related stress pathways to mitigate drug-induced toxicity and reverse resistance in breast cancer: A review.

International journal of biological macromolecules·2026

Exosomes as next-generation drug carriers: Transforming cancer therapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us